JANX

SEC source: 0001415889-24-018439 · form4-06282024_040637.xml · nonDerivative · entry 1

Barrett Ronald W · CIK 0001326330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,500

F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.

SEC source: 0001415889-24-018437 · form4-06282024_040633.xml · derivative · entry 2

CAPPS VICKIE L · CIK 0001248190 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,350

Underlying: Common Stock · 8,350 shares

Expires 2034-06-25

F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

SEC source: 0001415889-24-018437 · form4-06282024_040633.xml · nonDerivative · entry 1

CAPPS VICKIE L · CIK 0001248190 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,043

F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.

SEC source: 0001415889-24-015678 · form4-06052024_110623.xml · nonDerivative · entry 3

Lichter Jay · CIK 0001376355 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures SPV I, L.P.

Disclosed balance after: 3,340,018

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4 · ownership.nature: The shares are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the shares held by ABV SPV. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.

SEC source: 0001415889-24-015678 · form4-06052024_110623.xml · nonDerivative · entry 2

Lichter Jay · CIK 0001376355 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures I, LP

Disclosed balance after: 633,673

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the shares held by ABV I. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.

SEC source: 0001415889-24-015678 · form4-06052024_110623.xml · nonDerivative · entry 1

Lichter Jay · CIK 0001376355 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon Ventures XI, L.P.

Disclosed balance after: 3,271,216

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: The shares are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to have voting and investment power with respect to the shares held by Avalon Ventures. The Reporting Person is a managing member of Avalon XI GP and shares voting and investment power with respect to the shares held by Avalon Ventures. The Reporting Person disclaims beneficial ownership of all shares held by Avalon Ventures except to the extent of his actual pecuniary interest therein, if any.

SEC source: 0001415889-24-015676 · form4-06052024_110615.xml · nonDerivative · entry 2

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures SPV I, L.P.

Disclosed balance after: 3,340,018

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the shares held by ABV SPV. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.

SEC source: 0001415889-24-015676 · form4-06052024_110615.xml · nonDerivative · entry 1

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures I, LP

Disclosed balance after: 633,673

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: The shares are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the shares held by ABV I. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.

SEC source: 0001415889-24-015673 · form4-06052024_110653.xml · nonDerivative · entry 3

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures SPV I, L.P.

Disclosed balance after: 3,340,018

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4 · ownership.nature: The shares are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the shares held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-015673 · form4-06052024_110653.xml · nonDerivative · entry 2

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures I, LP

Disclosed balance after: 633,673

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the shares held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-015673 · form4-06052024_110653.xml · nonDerivative · entry 1

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,271,216

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.direct: The shares are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the shares held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-007006 · form4-03062024_040318.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,397,849

Underlying: Common Stock · 1,397,849 shares

Expires not disclosed

F1 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately and will be exercisable until exercise. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the issuer's Common Stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's Common Stock outstanding immediately after giving effect to such exercise.

F1 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately and will be exercisable until exercise. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the issuer's Common Stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's Common Stock outstanding immediately after giving effect to such exercise.

F1 · ownership.nature: The Pre-Funded Warrants have no expiration date and are exercisable immediately and will be exercisable until exercise. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the issuer's Common Stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's Common Stock outstanding immediately after giving effect to such exercise.

F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001415889-24-006428 · form4-03052024_120347.xml · nonDerivative · entry 9

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures GP LLC

Disclosed balance after: 0

F15 · kind: Represents a pro rata, in-kind distribution, and not a purchase or sale of securities, by ABV GP to its members without additional consideration.

F14 · ownership.nature: The shares are held directly by ABV GP. ABV GP is the general partner of ABV I. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-006428 · form4-03052024_120347.xml · nonDerivative · entry 8

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures GP LLC

Disclosed balance after: 1,700

F13 · kind: Represents receipt of shares in the distribution in kind described in footnote (11).

F14 · ownership.nature: The shares are held directly by ABV GP. ABV GP is the general partner of ABV I. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-006428 · form4-03052024_120347.xml · nonDerivative · entry 7

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures I, LP

Disclosed balance after: 764,869

F11 · kind: Represents a pro-rata, in kind distribution, and not a purchase or sale of securities, by Avalon BioVentures I, LP (ABV I) to its general partner and limited partners without additional consideration.

F12 · ownership.nature: The shares are held directly by ABV I. Avalon BioVentures GP, LLC (ABV GP) is the general partner of ABV I and may be deemed to beneficially own the shares held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-006428 · form4-03052024_120347.xml · nonDerivative · entry 6

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By ABV SPV I GP LLC

Disclosed balance after: 0

F10 · kind: Represents a pro rata, in-kind distribution, and not a purchase or sale of securities, by ABV SPV GP to its members without additional consideration.

F9 · ownership.nature: The shares are held directly by ABV SPV GP. ABV SPV GP is the general partner of ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-006428 · form4-03052024_120347.xml · nonDerivative · entry 5

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By ABV SPV I GP LLC

Disclosed balance after: 31,456

F8 · kind: Represents receipt of shares in the distribution in kind described in footnote (6).

F9 · ownership.nature: The shares are held directly by ABV SPV GP. ABV SPV GP is the general partner of ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-006428 · form4-03052024_120347.xml · nonDerivative · entry 4

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures SPV I, LP

Disclosed balance after: 4,031,543

F6 · kind: Represents a pro rata, in-kind distribution, and not a purchase or sale of securities by Avalon BioVentures SPV I, LP (ABV SPV) to its general partner and limited partners without additional consideration.

F7 · ownership.nature: The shares are directly held by ABV SPV. ABV SPV I GP LLC (ABV SPV GP) is the general partner of ABV SPV and may be deemed to beneficially own the shares held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-006428 · form4-03052024_120347.xml · nonDerivative · entry 3

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon Ventures XI GP LLC

Disclosed balance after: 0

F5 · kind: Represents a pro rata, in-kind distribution, and not a purchase or sale of securities, by Avalon XI GP to its members without additional consideration.

F4 · ownership.nature: The shares are held directly by Avalon XI GP. Avalon XI GP is the general partner of Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-006428 · form4-03052024_120347.xml · nonDerivative · entry 2

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon Ventures XI GP LLC

Disclosed balance after: 11,388

F3 · kind: Represents receipt of shares in the distribution in kind described in footnote (1).

F4 · ownership.nature: The shares are held directly by Avalon XI GP. Avalon XI GP is the general partner of Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-006428 · form4-03052024_120347.xml · nonDerivative · entry 1

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,948,495

F1 · kind: Represents a pro-rata, in-kind distribution, and not a purchase or sale of securities, by Avalon Ventures XI LP (Avalon Ventures) to its general partner and limited partners without additional consideration.

F2 · ownership.direct: The shares are held directly by Avalon Ventures. Avalon Ventures XI GP, LLC (Avalon XI GP) is the general partner of Avalon Ventures and may be deemed to beneficially own the shares held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-006305 · form4-03042024_090343.xml · nonDerivative · entry 1

Gujrathi Sheila · CIK 0001575202 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,028

F1 · kind: Represents receipt of securities in a pro rata, in-kind distribution, and not a purchase of securities, by ABV SPV I GP LLC, of which Reporting Person is a member.

SEC source: 0001415889-24-006293 · form4-03042024_090300.xml · nonDerivative · entry 1

CAPPS VICKIE L · CIK 0001248190 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,543

F1 · kind: Represents receipt of securities in a pro rata, in-kind distribution of securities, by ABV SPV I GP LLC, of which Reporting Person is a member.

SEC source: 0001209191-24-000438 · doc4.xml · derivative · entry 1

Robinson Byron · CIK 0001914899 · Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 151,500

Underlying: Common Stock · 151,500 shares

Expires 2034-01-01

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2025 and the balance will vest in equal monthly installments thereafter over a three year period.

SEC source: 0001209191-24-000426 · doc4.xml · derivative · entry 1

DiRaimondo Thomas · CIK 0002005618 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147,000

Underlying: Common Stock · 147,000 shares

Expires 2034-01-01

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2025 and the balance will vest in equal monthly installments thereafter over a three year period.

SEC source: 0001209191-24-000433 · doc4.xml · derivative · entry 1

Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 105,000 shares

Expires 2034-01-01

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2025 and the balance will vest in equal monthly installments thereafter over a three year period.

SEC source: 0001209191-24-000431 · doc4.xml · derivative · entry 1

Campbell David Alan · CIK 0001864158 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 356,500

Underlying: Common Stock · 356,500 shares

Expires 2034-01-01

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2025 and the balance will vest in equal monthly installments thereafter over a three year period.

SEC source: 0001209191-24-000440 · doc4.xml · derivative · entry 1

Winter Charles M. · CIK 0001960264 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,000

Underlying: Common Stock · 111,000 shares

Expires 2034-01-01

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2025 and the balance will vest in equal monthly installments thereafter over a three year period.

SEC source: 0001209191-24-000435 · doc4.xml · derivative · entry 1

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,000

Underlying: Common Stock · 157,000 shares

Expires 2034-01-01

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2025 and the balance will vest in equal monthly installments thereafter over a three year period.

SEC source: 0001209191-23-055083 · doc4.xml · nonDerivative · entry 1

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 849,854

F1 · ownership.nature: The shares are directly held by Avalon BioVentures I, LP (ABV I). Avalon BioVentures GP, LLC is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. Jay B. Lichter, Tighe M. Reardon, Sanford J. Madigan and Sergio G. Duron share voting and investment power with respect to the shares held by ABV I. Each of such individuals disclaims beneficial ownership of all shares held by ABV I except to the extent of each such individual's actual pecuniary interest therein, if any.

SEC source: 0001209191-23-055352 · doc4.xml · nonDerivative · entry 1

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 849,854

F1 · ownership.nature: The shares are directly held by Avalon BioVentures I, LP (ABV I). Avalon BioVentures GP LLC (ABV GP) is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. Mr. Reardon is a managing member of ABV GP and shares voting and investment power with respect to the shares held by ABV I. Mr. Reardon disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.

SEC source: 0001209191-23-055349 · doc4.xml · nonDerivative · entry 1

Lichter Jay · CIK 0001376355 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 849,854

F1 · ownership.nature: The shares are directly held by Avalon BioVentures I, LP (ABV I). Avalon BioVentures GP LLC (ABV GP) is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. Dr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the shares held by ABV I. Dr. Lichter disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.

SEC source: 0001104659-23-083069 · tm2321745-1_4seq1.xml · derivative · entry 3

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 503,226

Underlying: Common Stock · 503,226 shares

Expires not disclosed

F5 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately and will be exercisable until exercise. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the issuer's Common Stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.9% of the Issuer's Common Stock outstanding immediately after giving effect to such exercise.

F5 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately and will be exercisable until exercise. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the issuer's Common Stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.9% of the Issuer's Common Stock outstanding immediately after giving effect to such exercise.

F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F5 · ownership.nature: The Pre-Funded Warrants have no expiration date and are exercisable immediately and will be exercisable until exercise. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the issuer's Common Stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.9% of the Issuer's Common Stock outstanding immediately after giving effect to such exercise.

SEC source: 0001104659-23-083069 · tm2321745-1_4seq1.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 8,117,246

F1 · price: Acquired from the Issuer pursuant to the public offering described in the Issuer's Prospectus filed with the Securities and Exchange Commission on July 18, 2023.

F2 · balance_after: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F1 · ownership.nature: Acquired from the Issuer pursuant to the public offering described in the Issuer's Prospectus filed with the Securities and Exchange Commission on July 18, 2023.

F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001209191-23-037984 · doc4.xml · derivative · entry 1

Simson Jake · CIK 0001863094 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2033-06-13

F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2023, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders.

F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Advisor"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

SEC source: 0001104659-23-072338 · tm2318968-1_4seq1.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2033-06-13

F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2023, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders.

F1 · ownership.nature: The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2023, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F3 · ownership.nature: Under Mr. Simson's arrangement with the Adviser, Mr. Simson holds the option for the benefit of the Fund and the Nexus Fund II. Mr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock except to the extent of their pecuniary interest.

SEC source: 0001209191-23-037989 · doc4.xml · derivative · entry 1

Lichter Jay · CIK 0001376355 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2033-06-13

F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2023, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders.

SEC source: 0001209191-23-037987 · doc4.xml · derivative · entry 1

McNulty Alana B. · CIK 0001606086 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2033-06-13

F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2023, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders.

SEC source: 0001209191-23-037981 · doc4.xml · derivative · entry 1

Kung Winston · CIK 0001666963 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2033-06-13

F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2023, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders.

SEC source: 0001209191-23-037978 · doc4.xml · derivative · entry 1

Gujrathi Sheila · CIK 0001575202 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2033-06-13

F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2023, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders.

SEC source: 0001209191-23-037975 · doc4.xml · derivative · entry 1

CAPPS VICKIE L · CIK 0001248190 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2033-06-13

F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2023, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders.

SEC source: 0001209191-23-037972 · doc4.xml · derivative · entry 1

Barrett Ronald W · CIK 0001326330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2033-06-13

F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2023, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders.

SEC source: 0001209191-23-001885 · doc4.xml · derivative · entry 1

Robinson Byron · CIK 0001914899 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2033-01-02

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024 and the balance will vest in equal monthly installments thereafter over a three year period.

SEC source: 0001209191-23-001872 · doc4.xml · derivative · entry 1

Godfrey Wayne · CIK 0001866149 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2033-01-02

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024 and the balance will vest in equal monthly installments thereafter over a three year period.

SEC source: 0001209191-23-001878 · doc4.xml · derivative · entry 1

Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2033-01-02

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024 and the balance will vest in equal monthly installments thereafter over a three year period.

SEC source: 0001209191-23-001867 · doc4.xml · derivative · entry 1

Campbell David Alan · CIK 0001864158 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 310,000

Underlying: Common Stock · 310,000 shares

Expires 2033-01-02

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024 and the balance will vest in equal monthly installments thereafter over a three year period.

SEC source: 0001209191-23-001886 · doc4.xml · derivative · entry 1

Winter Charles M. · CIK 0001960264 · Chief Technical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2033-01-02

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024 and the balance will vest in equal monthly installments thereafter over a three year period.

SEC source: 0001209191-23-001882 · doc4.xml · derivative · entry 1

Reardon Tighe · CIK 0001760431 · Acting Chief Financial Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2033-01-02

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024 and the balance will vest in equal monthly installments thereafter over a three year period.

SEC source: 0001209191-22-051047 · doc4.xml · derivative · entry 2

Kung Winston · CIK 0001666963 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,375

Underlying: Common Stock · 9,375 shares

Expires 2032-09-20

F2 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over a one year period following September 21, 2022 (the "Grant Date") such that the option is fully vested on the first anniversary of the Grant Date.

SEC source: 0001209191-22-051047 · doc4.xml · derivative · entry 1

Kung Winston · CIK 0001666963 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2032-09-20

F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over a three year period following September 21, 2022 (the "Grant Date") such that the option is fully vested on the third anniversary of the Grant Date.